DCGI approves emergency use of Sputnik V, paves way for roll-out of 3rd COVID vaccine in India

Drug Controller General of India (DCGI), India's drug regulator, has granted approval for the emergency use of Russia’s Sputnik V vaccine in India, paving way for the roll-out of the third COVID-19 vaccine in India amid a sharp rise in coronavirus cases. The approval was granted after the Subject Expert Committee (SEC), constituted by the Central government, recommended Russia’s vaccine for emergency use authorisation in India. India is the 60th country to approve Russia’s Sputnik V vaccine. Sputnik V has an efficacy rate of 91.6 per cent. The DGCI has already approved two COVID-19 vaccines – indigenously developed Covaxin from Bharat Biotech, and Oxford-AstraZeneca's Covishield, manufactured by Serum Institute of India – for restricted emergency use in the country.